Iovance Biotherapeutics received FDA approval for a cancer drug, with its stock performance contrasting against the S&P 500 slide.

The entities involved

• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
• Iovance Biotherapeutics →

  American biopharmaceutical startup

  Nothing else this week.

• S&P →

  Japanese company

  • Buffett mentioned S&P as a historical information source, and Robert R. Johnson is a professor at Creighton University.Sun 12:13
  • Automated Insights reported that AES is based in Arlington and shares performance metrics compared to the S&P 500.Sun 09:11

Related events

• A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Jun 7
• Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.Jun 11
• The FDA recommended advancement for a new drug application submitted by a company.Jun 8
• GSK gained FDA clearance for a lung cancer medicine, while the FDA began reviewing other highly anticipated drugs.Aug 4
• Ligand Pharmaceuticals received FDA approval for its drug Filspari and was listed on the Nasdaq stock exchange.Sep 4